Reference(s)
Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Lung
Descriptor: In vitro studies


Reference Number: 93
Tsao, M. S. et al. Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer 20, 1-16 (1998).
PubMed link      E-mail link

Reference Number: 94
Maulik, G. et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 8, 620-7 (2002).
PubMed link      E-mail link

Reference Number: 95
Maulik, G. et al. Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. J Cell Mol Med 6, 539-53 (2002).
PubMed link      E-mail link

Reference Number: 96
Qiao, H. et al. Constitutive activation of met kinase in non-small-cell lung carcinomas correlates with anchorage-independent cell survival. J Cell Biochem 86, 665-77 (2002).
PubMed link      E-mail link

Reference Number: 97
Yi, S. et al. Paracrine effects of hepatocyte growth factor/scatter factor on non- small-cell lung carcinoma cell lines. Br J Cancer 77, 2162-70. (1998).
PubMed link      E-mail link

Reference Number: 225

Ma, P.C. et al.  c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63:6272-81 (2003).


PubMed link      E-mail link

Reference Number: 245
Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 22:415-65 (2003).
PubMed link      E-mail link

Reference Number: 369
Yoo MH, Xu XM, Carlson BA, Gladyshev VN, Hatfield DL. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J Biol Chem. 281, 13005-8 (2006)
PubMed link      E-mail link

Reference Number: 394
Hakuma N, Kinoshita I, Shimizu Y, Yamazaki K, Yoshida K, Nishimura M, Dosaka-Akita H. E1AF/PEA3 activates the Rho/Rho-associated kinase pathway to increase the malignancy potential of non-small-cell lung cancer cells. Cancer Res. 65, 10776-82 (2005)
PubMed link      E-mail link

Reference Number: 395
Sugimoto T, Takiguchi Y, Kurosu K, Kasahara Y, Tanabe N, Tatsumi K, Hiroshima K, Minamihisamatsu M, Miyamoto T, Kuriyama T. Growth factor-mediated interaction between tumor cells and stromal fibroblasts in an experimental model of human small-cell lung cancer. Oncol Rep. 14, 823-30 (2005)
PubMed link      E-mail link

Reference Number: 439
Masuda M, Kikuchi S, Maruyama T, Sakurai-Yageta M, Williams YN, Ghosh HP, Murakami Y. Tumor suppressor in lung cancer (TSLC)1 suppresses epithelial cell scattering and tubulogenesis. J Biol Chem. 280, 42164-71 (2005)
PubMed link      E-mail link

Reference Number: 533
Zhang YW, Staal B, Su Y, Swiatek P, Zhao P, Cao B, Resau J, Sigler R, Bronson R, Vande Woude GF. Evidence that MIG-6 is a tumor-suppressor gene. Oncogene. 26, 269-76 (2007)
PubMed link      E-mail link

Reference Number: 536
Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, Gibbs JB, Pan BS. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 67, 2081-8 (2007)
PubMed link      E-mail link

Reference Number: 546
Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, Salgia R. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer97, 368-77 (2007)
PubMed link      E-mail link

Reference Number: 550
Siegfried JM, Gubish CT, Rothstein ME, Queiroz de Oliveira PE, Stabile LP. Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer. Mol Pharmacol. 72, 769-79 (2007)
PubMed link      E-mail link

Reference Number: 560
Takahashi M, Sugiura T, Abe M, Ishii K, Shirasuna K. Regulation of c-Met signaling by the tetraspanin KAI-1/CD82 affects cancer cell migration. Int J Cancer. 121, 1919-29 (2007)
PubMed link      E-mail link

Reference Number: 561
Jagadeeswaran R, Jagadeeswaran S, Bindokas VP, Salgia R. Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol. 292, L1488-94 (2007)
PubMed link      E-mail link

Reference Number: 601
Chen JT, Huang CY, Chiang YY, Chen WH, Chiou SH, Chen CY, Chow KC. HGF Increases Cisplatin Resistance via Down-Regulation of AIF in Lung Cancer Cells. Am J Respir Cell Mol Biol. 38, 559-65 (2008)
PubMed link      E-mail link

Reference Number: 602
Pierce A, Barron N, Linehan R, Ryan E, O'Driscoll L, Daly C, Clynes M. Identification of a novel, functional role for S100A13 in invasive lung cancer cell lines. Eur J Cancer. 44, 151-9 (2008)
PubMed link      E-mail link

Reference Number: 608
Guo A, Villén J, Kornhauser J, Lee KA, Stokes MP, Rikova K, Possemato A, Nardone J, Innocenti G, Wetzel R, Wang Y, MacNeill J, Mitchell J, Gygi SP, Rush J, Polakiewicz RD, Comb MJ. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A. 105, 692-7 (2008)
PubMed link      E-mail link

Reference Number: 751
Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer. 10, 281-9 (2009)
PubMed link      E-mail link

Reference Number: 932
Okamoto W, Okamoto I, Tanaka K, Hatashita E, Yamada Y, Kuwata K, Yamaguchi H, Arao T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K. TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Mol Cancer Ther. 9, 2785-92 (2010)
PubMed link      E-mail link

Reference Number: 937
Argast GM, Mercado P, Mulford IJ, O'Connor M, Keane DM, Shaaban S, Epstein DM, Pachter JA, Kan JL. Cooperative signaling between oncostatin M, hepatocyte growth factor and transforming growth factor-ß enhances epithelial to mesenchymal transition in lung and pancreatic tumor models. Cells Tissues Organs. 193, 114-32 (2011)
PubMed link      E-mail link

Reference Number: 960
Gentile A, Lazzari L, Benvenuti S, Trusolino L, Comoglio PM. Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res. 71, 3132-41 (2011)
PubMed link      E-mail link

Reference Number: 975
Lu Z, Ding L, Hong H, Hoggard J, Lu Q, Chen YH. Claudin-7 inhibits human lung cancer cell migration and invasion through ERK/MAPK signaling pathway. Exp Cell Res. 317, 1935-46 (2011)
PubMed link      E-mail link

Reference Number: 989
Szabo R, Rasmussen AL, Moyer AB, Kosa P, Schafer JM, Molinolo AA, Gutkind JS, Bugge TH. c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase. Oncogene. 30, 2003-16 (2011)
PubMed link      E-mail link

Reference Number: 1051
Tanizaki J, Okamoto I, Sakai K, Nakagawa K. Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. Br J Cancer. 105, 807-13 (2011)
PubMed link      E-mail link

Reference Number: 1079
Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 17, 77-88 (2010)
PubMed link      E-mail link

Reference Number: 1133
Watanabe K, Emoto N, Hamano E, Sunohara M, Kawakami M, Kage H, Kitano K, Nakajima J, Goto A, Fukayama M, Nagase T, Yatomi Y, Ohishi N, Takai D. Genome structure-based screening identified epigenetically silenced microRNA associated with invasiveness in non-small-cell lung cancer. Int J Cancer. 130, 2580-90 (2012)
PubMed link      E-mail link

Reference Number: 1216
Koizumi H, Yamada T, Takeuchi S, Nakagawa T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Yano S. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis. J Thorac Oncol. 7, 1078-85 (2012)
PubMed link      E-mail link

Reference Number: 1228
Liu Y, Shi QF, Qi M, Tashiro S, Onodera S, Ikejima T. Interruption of hepatocyte growth factor signaling augmented oridonin-induced death in human non-small cell lung cancer A549 cells via c-met-nuclear factor-?B-cyclooxygenase-2 and c-Met-Bcl-2-caspase-3 pathways. Biol Pharm Bull. 35, 1150-8 (2012)
PubMed link      E-mail link

Reference Number: 1229
Liu Y, Yang Y, Ye YC, Shi QF, Chai K, Tashiro S, Onodera S, Ikejima T. Activation of ERK-p53 and ERK-mediated phosphorylation of Bcl-2 are involved in autophagic cell death induced by the c-Met inhibitor SU11274 in human lung cancer A549 cells. J Pharmacol Sci. 118, 423-32 (2012)
PubMed link      E-mail link

Reference Number: 1288
Wang LG, Ni Y, Su BH, Mu XR, Shen HC, Du JJ. MicroRNA-34b functions as a tumor suppressor and acts as a nodal point in the feedback loop with Met. Int J Oncol. 42, 957-62 (2013)
PubMed link      E-mail link

Reference Number: 1289
Voortman J, Harada T, Chang RP, Killian JK, Suuriniemi M, Smith WI, Meltzer PS, Lucchi M, Wang Y, Giaccone G. Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors. Curr Pharm Des. 19, 833-40 (2013)
PubMed link      E-mail link

Reference Number: 1309
Michikoshi H, Nakamura T, Sakai K, Suzuki Y, Adachi E, Matsugo S, Matsumoto K. a-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells. Cancer Lett. 335, 472-8 (2013)
PubMed link      E-mail link

Reference Number: 1343
Lee JM1, Yoo JK, Yoo H, Jung HY, Lee DR, Jeong HC, Oh SH, Chung HM, Kim JK. The novel miR-7515 decreases the proliferation and migration of human lung cancer cells by targeting c-Met. Mol Cancer Res. 11, 43-53 (2013)
PubMed link      E-mail link

Reference Number: 1360
Radtke S1, Milanovic M, Rossé C, De Rycker M, Lachmann S, Hibbert A, Kermorgant S, Parker PJ. ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines. J Cell Sci. 126, 2381-91 (2013)
PubMed link      E-mail link

Reference Number: 1380
Chan B1, VanderLaan PA, Sukhatme VP. 6-Phosphogluconate dehydrogenase regulates tumor cell migration in vitro by regulating receptor tyrosine kinase c-Met. Biochem Biophys Res Commun. 439, 247-51 (2013)
PubMed link      E-mail link

Reference Number: 1483
Liu Y, Liu JH, Chai K, Tashiro S, Onodera S, Ikejima T. J Pharm Pharmacol. Inhibition of c-Met promoted apoptosis, autophagy and loss of the mitochondrial transmembrane potential in oridonin-induced A549 lung cancer cells. J Pharm Pharmacol. 65, 1622-42 (2013)
PubMed link      E-mail link

Reference Number: 1488
Zhou JY, Chen X, Zhao J, Bao Z, Chen X, Zhang P, Liu ZF, Zhou JY. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET. Cancer Lett. 351, 265-71 (2014)
PubMed link      E-mail link

Reference Number: 1507
Sakai A, Kasahara K, Ohmori T, Kimura H, Sone T, Fujimura M, Nakao S. MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity. J Thorac Oncol. 7, 1337-44 (2012)
PubMed link      E-mail link

Reference Number: 1514
Wu W, Bi C, Credille KM, Manro JR, Peek VL, Donoho GP, Yan L, Wijsman JA, Yan SB, Walgren RA. Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET. Clin Cancer Res. 19, 5699-710 (2013)
PubMed link      E-mail link

Reference Number: 1554
Cañadas I, Rojo F, Taus Á, Arpí O, Arumí-Uría M, Pijuan L, Menéndez S, Zazo S, Dómine M, Salido M, Mojal S, García de Herreros A, Rovira A, Albanell J, Arriola E. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer. Clin Cancer Res. 20, 938-50 (2014)
PubMed link      E-mail link

Reference Number: 1555
Whitsett TG, Fortin Ensign SP, Dhruv HD, Inge LJ, Kurywchak P, Wolf KK, LoBello J, Kingsley CB, Allen JW, Weiss GJ, Tran NL. FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion. Clin Exp Metastasis. 31, 613-23 (2014)
PubMed link      E-mail link

Reference Number: 1573
Chiang YY, Chow KC, Lin TY, Chiang IP, Fang HY. Hepatocyte growth factor and HER2/neu downregulate expression of apoptosis-inducing factor in non-small cell lung cancer. Oncol Rep. 31, 597-604 (2014)
PubMed link      E-mail link

Reference Number: 1576
Ekert JE, Johnson K, Strake B, Pardinas J, Jarantow S, Perkinson R, Colter DC. Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro--implication for drug development. PLoS One. 9, e92248 (2014
PubMed link      E-mail link

Reference Number: 1578
Rolle CE, Kanteti R, Surati M, Nandi S, Dhanasingh I, Yala S, Tretiakova M, Arif Q, Hembrough T, Brand TM, Wheeler DL, Husain AN, Vokes EE, Bharti A, Salgia R. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. Mol Cancer Ther. 13, 576-84 (2014)
PubMed link      E-mail link

Reference Number: 1888
Montagne R, Berbon M, Doublet L, Debreuck N, Baranzelli A, Drobecq H, Leroy C, Delhem N, Porte H, Copin MC, Dansin E, Furlan A, Tulasne D. Necrosis- and apoptosis-related Met cleavages have divergent functional consequences. Cell Death Dis. 6, e1769 (2015)
PubMed link      E-mail link

Reference Number: 1890
Zhen Q, Liu J, Gao L, Liu J, Wang R, Chu W, Zhang Y, Tan G, Zhao X, Lv B. MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer. Cytogenet Genome Res. 146, 1-8 (2015)
PubMed link      E-mail link